Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of intranasal etripamil for ventricular rate reduction in atrial fibrillation
NL-OMON51562Phase 2Active, not recruiting
- Sponsor
- Milestone Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of etripamil in Atrial fibrillation (AFib), sponsored by Milestone Pharmaceuticals. Started Feb 2023; status: active, not recruiting.
02
Drugs
etripamil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON51562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51562.